# A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

> **NCT03988036** · PHASE2 · COMPLETED · sponsor: **West German Study Group** · enrollment: 46 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Trastuzumab Biosimilar ABP 980
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT03988036
- **Lead sponsor:** West German Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-18
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03988036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03988036, "A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03988036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*